Clinical Trials Logo

Corneal Defect clinical trials

View clinical trials related to Corneal Defect.

Filter by:
  • None
  • Page 1

NCT ID: NCT05626478 Recruiting - Corneal Edema Clinical Trials

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT ID: NCT05458661 Not yet recruiting - Cataract Clinical Trials

Feasibility Investigation of Biometry and Tomography Measurements in a Heterogeneous Patient Cohort

BioBase
Start date: August 2022
Phase: N/A
Study type: Interventional

The planned clinical investigation will be conducted to acquire raw data for the development of the algorithm. The data acquisition is intended to obtain first impressions of the potential performance of the changed hardware and software components and to confirm the safety profile assessed by risk analysis.

NCT ID: NCT05204329 Recruiting - Cornea Clinical Trials

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

MSCSecretome
Start date: January 24, 2024
Phase: Early Phase 1
Study type: Interventional

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.

NCT ID: NCT04975971 Completed - Cataract Senile Clinical Trials

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

Start date: March 9, 2021
Phase:
Study type: Observational

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery

NCT ID: NCT04626583 Recruiting - Safety Clinical Trials

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Start date: March 5, 2021
Phase: Phase 1
Study type: Interventional

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing.

NCT ID: NCT04521140 Completed - Clinical trials for Intraocular Pressure

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

Start date: October 16, 2020
Phase: Phase 4
Study type: Interventional

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1%.

NCT ID: NCT04228926 Recruiting - Corneal Defect Clinical Trials

Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects

Start date: December 24, 2020
Phase: Phase 2
Study type: Interventional

The subjects of this study were patients who underwent corneal endothelial transplantation,who were randomly divided into 3 groups, 2 groups (0.002% and 0.004% ZKY001 eye drops) and 1 placebo control group.

NCT ID: NCT03967548 Completed - Corneal Defect Clinical Trials

The Germinal Peptide Eye Drops in Healthy Volunteers in a Clinical Study

Start date: April 9, 2021
Phase: Phase 1
Study type: Interventional

The subjects of this study were healthy subjects, who were given medicine in a single dose group: 0.004%.

NCT ID: NCT03662971 Completed - Corneal Defect Clinical Trials

Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

Phase I Clinical Trial to Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers.